McKesson Corporation
MCKBusiness Overview
source: coverage-next-full ticker: MCK step: "01" title: Business Overview — Segments, Model, Strategic Position created: 2026-05-29
Step 01 — Business Overview
Company Description
McKesson Corporation is the largest pharmaceutical distributor in the United States and one of the largest companies in the world by revenue (~$309B in FY2024). Founded in 1833 as a drug wholesaler in New York, McKesson has evolved into a diversified healthcare infrastructure company spanning pharmaceutical distribution, specialty logistics, pharmacy technology, and oncology services.
At its core, McKesson is a logistics and supply chain company operating at the intersection of pharmaceutical manufacturers and end-point care delivery. It buys drugs from ~1,500 manufacturers, warehouses them across ~32 distribution centers in the US, and delivers to ~40,000 pharmacy and healthcare provider locations — generating a spread between purchase and sale price, plus fees for ancillary services.
Mission: "Advancing Health Outcomes for All."
Business Segments (FY2024)
1. US Pharmaceutical (~85% of Revenue, ~65% of Adjusted Operating Profit)
The core distribution business. McKesson distributes branded and generic pharmaceuticals, specialty drugs, and over-the-counter products to:
- Retail national accounts: CVS, Rite Aid (primary distributor), other pharmacy chains
- Independent pharmacies: Community pharmacies (often enrolled in Health Mart franchise)
- Institutional: Hospitals, health systems, long-term care facilities
- Specialty providers: Oncology practices, specialty clinics, physician offices
Key economics: Branded drug distribution earns a fee-for-service spread (~1-2% of drug value, declining with drug price inflation on a dollar basis but growing on unit volume). Generic drugs earn wider spreads; ClarusONE JV (with WBA) consolidates generic purchasing to extract manufacturer discounts. GLP-1 drugs (Ozempic, Wegovy, Mounjaro) have become a rapidly growing distribution category.
Oncology Platform (within US Pharma but tracked separately):
- US Oncology Network: Largest community oncology network in the US with ~2,000 affiliated physicians across ~600 practices. Physicians remain independent but get group purchasing, billing, and operational support. Revenue recognized as drugs distributed to these practices.
- Ontada: Oncology data and technology platform; collects real-world evidence from US Oncology practices to support manufacturers and payers. Small revenue but strategic for margin enhancement.
- Specialty drug distribution (biosimilars, oncology, rare disease) is the highest-growth, highest-margin sub-segment within US Pharma.
2. Prescription Technology Solutions (RxTS) (~3-4% of Revenue, ~15% of Adjusted Operating Profit)
Technology and services that sit between pharmacy, payer, and manufacturer:
- CoverMyMeds: Electronic prior authorization platform; one of the largest in the US; processes ~19M+ prior authorization requests/year
- RelayHealth Pharmacy: Pharmacy connectivity network connecting pharmacies, payers, and PBMs
- AccessMed/RxCrossroads: Patient access programs, HUB services (reimbursement support for specialty drugs)
- Biologics Direct: Direct-to-patient specialty pharmacy fulfillment
RxTS earns technology fees from payers and manufacturers. Highest-margin segment; benefiting from complexity growth in specialty drug access.
3. Medical-Surgical Solutions (~6-7% of Revenue, ~10% of Adjusted Operating Profit)
Distributes medical-surgical supplies, lab products, and equipment to:
- Physician offices, surgery centers, long-term care, home care settings
- Built around acquisition of PSS World Medical and MedPartners
Primary customer: US government COVID-19 vaccine/test distribution program (now substantially wound down; created a large but temporary revenue/profit tailwind in FY2021–FY2023).
4. International (~4-5% of Revenue, diminishing)
McKesson has been exiting European pharmaceutical distribution operations:
- Divested German wholesale (Celesio/LLOYDS) operations
- Retaining Canadian operations (McKesson Canada) and limited European operations
- Segment is being wound down; management expects International contribution to become minimal by FY2026
Revenue by Customer Type (Approximate, FY2024)
| Customer Type | % of Revenue |
|---|---|
| Retail Chains (CVS, Rite Aid, etc.) | ~45% |
| Institutional (hospitals, health systems) | ~25% |
| Independent/Community Pharmacies | ~15% |
| Specialty/Oncology Practices | ~10% |
| Other (government, international) | ~5% |
Strategic Positioning
Core thesis: McKesson is migrating from commodity distributor to a healthcare infrastructure platform. The key transition is the growing weight of:
- Specialty distribution (higher margin, higher barriers to entry)
- US Oncology Network (recurring physician group relationships, data moat)
- RxTS technology layer (software economics, recurring SaaS-like fees)
Management has guided to double-digit Adjusted EPS growth through FY2027 driven by:
- Specialty volume growth outpacing branded drug inflation
- GLP-1 drug tailwind (volume + distribution of new blockbusters)
- Share buybacks reducing share count ~7% annually
- RxTS and Oncology as mix-shift drivers toward higher margins
Competitive Position
McKesson commands ~33% of US pharmaceutical wholesale revenue, making it the largest of the "Big Three" distributors (MCK, COR/AmerisourceBergen, CAH/Cardinal Health). The market is an effective oligopoly — no new entrant has successfully entered at scale in 30+ years due to massive capital requirements, relationship lock-in, and thin margins that require scale to be profitable.
Recent Strategic Actions (FY2023–FY2025)
- Continued divestiture of European operations (RxTS Europe sold)
- Closed acquisition of Rx Savings Solutions (pharmacy cost transparency, employer benefits)
- Expanded US Oncology Network (added ~200 physicians FY2023–FY2024)
- Launched Ontada as formal brand for oncology data/analytics business
- Continued $3–4B+ annual share repurchase programs
- Settled national opioid litigation ($7.9B over 18 years, ~$440M/year)
Financial Snapshot
source: coverage-next-full ticker: MCK step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
Step 04 — Financial Snapshot
3-Year Income Statement Summary
All figures in USD millions unless noted. McKesson fiscal year ends March 31.
Income Statement (GAAP)
| Metric | FY2022 | FY2023 | FY2024 | 2-yr CAGR |
|---|---|---|---|---|
| Revenue | $238,228M | $276,251M | $308,952M | +13.8% |
| Cost of Sales | $229,281M | $266,303M | $297,832M | +13.9% |
| Gross Profit | $8,947M | $9,948M | $11,120M | +11.6% |
| Gross Margin | 3.75% | 3.60% | 3.60% | — |
| Operating Expenses (SG&A + Amort) | $5,842M | $6,183M | $6,564M | +6.0% |
| Opioid Charges & Restructuring | $274M | $191M | $165M | — |
| GAAP Operating Income | $2,831M | $3,574M | $4,391M | +24.5% |
| GAAP Operating Margin | 1.19% | 1.29% | 1.42% | — |
| Interest & Other (net) | ($268M) | ($209M) | ($265M) | — |
| GAAP Pre-Tax Income | $2,563M | $3,365M | $4,126M | +26.9% |
| Income Tax Expense | ($639M) | ($862M) | ($993M) | — |
| Effective Tax Rate | 24.9% | 25.6% | 24.1% | — |
| GAAP Net Income | $1,707M | $2,306M | $2,859M | +29.4% |
| GAAP EPS (diluted) | $11.86 | $16.71 | $21.72 | +35.4% |
| Diluted Shares Outstanding | 143.9M | 138.0M | 131.6M | -4.5% |
Adjusted (Non-GAAP) P&L
McKesson's primary reporting metric is Adjusted Operating Profit and Adjusted EPS. These exclude: opioid litigation charges, amortization of acquisition-related intangibles, restructuring charges, and certain discrete tax items.
| Metric | FY2022 | FY2023 | FY2024 | 2-yr CAGR |
|---|---|---|---|---|
| Adjusted Operating Profit | $4,146M | $4,440M | $5,100M | +11.1% |
| Adjusted Operating Margin | 1.74% | 1.61% | 1.65% | — |
| Adjusted Interest/Other (net) | ($165M) | ($178M) | ($208M) | — |
| Adjusted Pre-Tax Income | $3,981M | $4,262M | $4,892M | +10.8% |
| Adjusted Tax | ($890M) | ($950M) | ($1,116M) | — |
| Adjusted Effective Tax Rate | 22.4% | 22.3% | 22.8% | — |
| Adjusted Net Income | $3,091M | $3,312M | $3,776M | +10.4% |
| Adjusted EPS (diluted) | $22.95 | $26.00 | $31.22 | +16.7% |
Note: GAAP EPS grew faster than Adjusted EPS in FY2022→FY2024 due to reversal of prior opioid charge accruals and lower prior-year GAAP base.
Profitability Analysis
Margin Structure
McKesson operates with razor-thin margins by design — it is a distribution business where scale, not margin, drives profitability. The key metrics are:
| Metric | FY2022 | FY2023 | FY2024 | Commentary |
|---|---|---|---|---|
| GAAP Gross Margin | 3.75% | 3.60% | 3.60% | Stable; slight pressure from branded drug mix |
| Adjusted Operating Margin | 1.74% | 1.61% | 1.65% | Slight recovery as RxTS/Oncology grow |
| RxTS Segment Margin | ~18% | ~19% | ~20% | High-margin software/tech layer |
| US Pharma Segment Margin | ~1.2% | ~1.2% | ~1.2% | Stable distribution margin |
| Med-Surg Segment Margin | ~7.5% | ~6.5% | ~6.4% | Post-COVID normalization pressure |
Key insight: Adjusted EPS growing at 16–17% CAGR despite revenue growing at ~14% reflects operating leverage + ~4–5% annual share count reduction via buybacks.
EPS Bridge (FY2023 → FY2024)
| Component | Impact on Adjusted EPS |
|---|---|
| US Pharma profit growth | +$2.90 |
| RxTS profit growth | +$0.60 |
| Med-Surg profit decline | -$0.50 |
| International improvement | +$0.15 |
| Interest expense (higher debt) | -$0.25 |
| Share count reduction (~5%) | +$1.35 |
| Tax rate change | +$0.97 |
| Total Adjusted EPS change | +$5.22 ($26.00 → $31.22) |
Cash Flow Summary
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Operating Cash Flow | $4,018M | $4,243M | $4,847M |
| Capital Expenditures | ($594M) | ($705M) | ($831M) |
| Free Cash Flow | $3,424M | $3,538M | $4,016M |
| FCF Margin (on revenue) | 1.44% | 1.28% | 1.30% |
| FCF Conversion (FCF/Adj. Net Income) | 110.8% | 106.8% | 106.3% |
FCF quality: Highly consistent. FCF slightly exceeds Adjusted Net Income due to working capital benefits (McKesson collects from customers faster than it pays manufacturers in some programs). Capex is primarily IT/distribution infrastructure; moderate and predictable.
Balance Sheet Highlights (FY2024)
| Item | Amount | Notes |
|---|---|---|
| Cash & Equivalents | $3.8B | Available for buybacks/M&A |
| Total Assets | $67.2B | ~65% current assets (inventory, receivables) |
| Total Debt (gross) | $8.9B | Mix of senior notes, term loans |
| Net Debt | ~$5.1B | Gross debt minus cash |
| Total Equity | $3.2B | Low due to accumulated buybacks reducing book equity |
| Net Debt / Adjusted EBITDA | ~0.9x | Conservative leverage; investment grade |
FY2025 and FY2026 Outlook (Consensus/Guidance)
McKesson guided FY2025 Adjusted EPS of $37.00–$37.80 (midpoint ~$37.40), implying ~19–21% growth from FY2024's $31.22.
| Metric | FY2025E | FY2026E |
|---|---|---|
| Revenue | ~$340B | ~$370B |
| Adjusted Operating Profit | ~$5.8B | ~$6.5B |
| Adjusted EPS | ~$37.40 | ~$43.00 |
| EPS Growth | ~20% | ~15% |
| FCF | ~$4.5–5.0B | ~$5.0–5.5B |
Note: MCK typically guides conservatively and has a multi-year history of beating initial guidance.
Key Financial Ratios
| Ratio | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| P/E (GAAP, year-end price) | ~16x | ~18x | ~19x |
| P/E (Adjusted, year-end price) | ~17x | ~18x | ~19x |
| EV/EBITDA | ~14x | ~14x | ~15x |
| Price/FCF | ~17x | ~18x | ~19x |
| Net Debt/EBITDA | 1.1x | 1.0x | 0.9x |
| Dividend Yield | ~0.5% | ~0.5% | ~0.4% |
Year-end prices approximate based on fiscal year-end (March 31) closing prices.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $MCK.